Research programme: pneumococcal polysaccharide vaccine 24-valent - Sinovac Biotech

Drug Profile

Research programme: pneumococcal polysaccharide vaccine 24-valent - Sinovac Biotech

Alternative Names: 24-valent pneumococcal polysaccharide vaccine - Sinovac Biotech; Pneumococcal 24-valent vaccine - Sinovac Biotech; Pneumococcal polysaccharides vaccine - Sinovac Biotech; PPV - Sinovac Biotech

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sinovac Biotech
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pneumococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections in China (Parenteral)
  • 21 May 2014 Sinovac Biotech plans a phase I trial for Pneumococcal infections in China
  • 01 May 2014 China FDA approves Clinical Trial Application for 24-valent Pneumococcal polysaccharide vaccine candidates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top